Pharma Services deal seals MDS exit from contract research #solvay #pharma

Posted On Nov 10 2017 by

#mds pharma services # Pharma Services deal seals MDS exit from contract research Canadian life sciences company MDS has found buyers for the rest of its MDS Pharma Services unit, rounding off its exit strategy for the contract research sector. MDS will divest the remaining Early Stage components of its US-based contract research organisation (CRO) to Ricerca Biosciences and private investors for US$45 million as well as a minority interest in a new corporation being set up for the transaction. The deal, which is expected to close within two months, does not include MDS Pharma Services’ Early Stage Development facility …


Pharma Services deal seals MDS exit from contract research #mankind #pharma

Posted On May 19 2017 by

#mds pharma services # Pharma Services deal seals MDS exit from contract research Canadian life sciences company MDS has found buyers for the rest of its MDS Pharma Services unit, rounding off its exit strategy for the contract research sector. MDS will divest the remaining Early Stage components of its US-based contract research organisation (CRO) to Ricerca Biosciences and private investors for US$45 million as well as a minority interest in a new corporation being set up for the transaction. The deal, which is expected to close within two months, does not include MDS Pharma Services’ Early Stage Development facility …


Pharma Services deal seals MDS exit from contract research #generic #pharma #companies

Posted On Apr 24 2017 by

#mds pharma services # Pharma Services deal seals MDS exit from contract research Canadian life sciences company MDS has found buyers for the rest of its MDS Pharma Services unit, rounding off its exit strategy for the contract research sector. MDS will divest the remaining Early Stage components of its US-based contract research organisation (CRO) to Ricerca Biosciences and private investors for US$45 million as well as a minority interest in a new corporation being set up for the transaction. The deal, which is expected to close within two months, does not include MDS Pharma Services’ Early Stage Development facility …


Pharma Services deal seals MDS exit from contract research #new #pharmaceutical #companies #2013

Posted On Feb 8 2017 by

#mds pharma services # Pharma Services deal seals MDS exit from contract research Canadian life sciences company MDS has found buyers for the rest of its MDS Pharma Services unit, rounding off its exit strategy for the contract research sector. MDS will divest the remaining Early Stage components of its US-based contract research organisation (CRO) to Ricerca Biosciences and private investors for US$45 million as well as a minority interest in a new corporation being set up for the transaction. The deal, which is expected to close within two months, does not include MDS Pharma Services’ Early Stage Development facility …


Pharma Services deal seals MDS exit from contract research #alnylam #pharma

Posted On Jan 11 2017 by

#mds pharma services # Pharma Services deal seals MDS exit from contract research Canadian life sciences company MDS has found buyers for the rest of its MDS Pharma Services unit, rounding off its exit strategy for the contract research sector. MDS will divest the remaining Early Stage components of its US-based contract research organisation (CRO) to Ricerca Biosciences and private investors for US$45 million as well as a minority interest in a new corporation being set up for the transaction. The deal, which is expected to close within two months, does not include MDS Pharma Services’ Early Stage Development facility …


Pharma Services deal seals MDS exit from contract research #top #drug #manufacturers

Posted On Nov 26 2016 by

#mds pharma services # Pharma Services deal seals MDS exit from contract research Canadian life sciences company MDS has found buyers for the rest of its MDS Pharma Services unit, rounding off its exit strategy for the contract research sector. MDS will divest the remaining Early Stage components of its US-based contract research organisation (CRO) to Ricerca Biosciences and private investors for US$45 million as well as a minority interest in a new corporation being set up for the transaction. The deal, which is expected to close within two months, does not include MDS Pharma Services’ Early Stage Development facility …